Cytoprotective Agent RNS60 Receives Fast Track Designation for Ischemic Stroke Treatment
Written by
Neurology Live
Published
0
comments
0
min
Revalesio's RNS60 gains FDA fast track status, offering a groundbreaking approach to neuroprotection in ischemic stroke treatment.